Learning Hub

< BACK iPROLEPSIS Games Showcased at Lisboa Games Week 2025 Nov 24, 2025 The FMH/IST-ULisboa team presented the iPROLEPSIS Games, connecting with the gaming community and industry stakeholders The iPROLEPSIS Games were presented at Lisboa Games Week 2025 , held from 20–23 November in Portugal. The team from Faculdade de Motricidade Humana / Instituto Superior Técnico – ULisboa (Bárbara Ramalho, Samuel Gomes, Marta Vicente, Filipa Magalhães and Rodolfo Costa) showcased the serious games developed within the project. Lisboa Games Week is an event that reinforces the role of academic and professional training in the video game industry. Educational institutions present courses, projects, and programmes related to video game development, digital art, programming, design, animation, sound, virtual reality, artificial intelligence, and other technological and creative fields. The programme includes exhibitions, practical demonstrations, vocational guidance sessions, talks, and opportunities for direct contact with industry. Participation in this event provided a platform for presenting the iPROLEPSIS Games within a setting focused on education, creativity, and technological development. 🔗 https://lisboagamesweek.pt/ LGWPhoto4.jpeg LGWPhoto3.jpeg LGWPhoto3.jpeg LGWPhoto4.jpeg 1/4 PREVIOUS NEXT

iPROLEPSIS project newsletter Nov 6, 2025 Issue No. 10 iPROLEPSIS project newsletter No 10 Welcome! This is the 10th edition of the iPROLEPSIS newsletter, where we share the latest updates and progress from the project. READ THE NEWSLETTER Jul 1, 2025 Issue No. 9 iPROLEPSIS project newsletter No 9 Welcome! This is the 9th edition of the iPROLEPSIS newsletter, where we share the latest updates and progress from the project. READ THE NEWSLETTER Apr 28, 2025 Issue No. 8 iPROLEPSIS project newsletter No 8 Welcome! This is the 8th edition of the iPROLEPSIS newsletter, where we share the latest updates and progress from the project. READ THE NEWSLETTER Jan 28, 2025 Issue No. 7 iPROLEPSIS project newsletter No 7 Welcome! This is the 7th edition of the Newsletter series of the iPROLEPSIS project. In this issue, we highlight the insights on the future of digital biomarkers in rheumatology care, offer key information about PsA and practical advice to improve daily life, update about past events. READ THE NEWSLETTER Oct 9, 2024 Issue No. 6 iPROLEPSIS project newsletter No 6 Welcome! This is the 6th edition of the Newsletter series of the iPROLEPSIS project. In this issue, we highlight the release of the miPROLEPSIS and miPROLEPSIS Joint Landmarker apps, recent publications, reflections on Psoriatic Arthritis Awareness Day and Psoriasis Awareness Month, and key takeaways from recent events. READ THE NEWSLETTER Jul 9, 2024 Issue No. 5 iPROLEPSIS project newsletter No 5 Welcome! This is the 5th edition of the Newsletter series of the iPROLEPSIS project. In this newsletter issue, we delve into the updates and progress of the project activities, synergies and events. READ THE NEWSLETTER Mar 7, 2024 Issue No. 4 iPROLEPSIS project newsletter No 4 Welcome! This is the 4th edition of the Newsletter series of the iPROLEPSIS project. Let's explore the latest developments and advancements in our project activities, collaborations, and upcoming events. READ THE NEWSLETTER Nov 30, 2023 Issue No. 3 iPROLEPSIS project newsletter No 3 Welcome! This is the 3rd edition of the Newsletter series of the iPROLEPSIS project. In this newsletter issue, we delve into the updates and progress of the project activities, synergies and events. READ THE NEWSLETTER Sep 5, 2023 Issue No. 2 iPROLEPSIS project newsletter No 2 Welcome! This is the 2nd edition of the Newsletter series of the iPROLEPSIS project. In this newsletter issue, we delve into the transformative power of user research and co-creation in the healthcare innovation research process. READ THE NEWSLETTER Jul 3, 2023 Issue No. 1 iPROLEPSIS project newsletter No 1 Welcome! This is the 1st edition of the newsletter series of the iPROLEPSIS project! The 1st newsletter informs you about the iPROLEPSIS project, its vision, pillars and objectives, and the partners involved. READ THE NEWSLETTER

< BACK iPROLEPSIS Research on Digital Rheumatology Published in The Lancet eClinicalMedicine May 19, 2025 New Publication Highlights Explainable AI Tools, Digital Biomarkers, and Multimodal Disease Monitoring for PsA A recent paper published in The Lancet eClinicalMedicine presents the iPROLEPSIS initiative as a comprehensive European research effort aimed at transforming the diagnosis and management of psoriatic arthritis (PsA) through digital innovation and patient-centred care . The paper, titled "European advances in digital rheumatology: explainable insights and personalized digital health tools for psoriatic arthritis", outlines how iPROLEPSIS addresses critical gaps in current PsA care by combining real-world data , wearable sensors , and explainable artificial intelligence (xAI) models. Abstract The shift from traditional to technology-based diagnosis and management of psoriatic arthritis (PsA) represents a significant evolution in patient care. Traditionally, PsA was diagnosed and managed through clinical evaluations, physical examinations, and basic imaging techniques. With the evolution of digital technologies, PsA care is transforming, giving rise to the field of digital rheumatology. In this vein, Europe has invested in research initiatives, like iPROLEPSIS, that could accelerate this transformation and redefine PsA care within a digital world. In this Viewpoint we present the current clinical PsA landscape, highlight the PsA patients’ interaction with the digital world, and showcase the novel iPROLEPSIS digital offerings. The latter scaffold digital rheumatology by identifying PsA key drivers. Moreover, they support personalized PsA risk prediction and improve early PsA detection. Furthermore, they enable precise PsA treatment strategies and digital therapeutics within a novel digital health ecosystem. Read the full paper here: https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(25)00175-0/fulltext PIIS2589537025001750 .pdf Download PDF • 1.20MB Lancet publication.png Lancet publication.png 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS presented at the MULTIPULM project kick-off meeting Oct 8, 2025 iPROLEPSIS tools to be adapted for clinical studies in Brazil, Serbia, and Türkiye The iPROLEPSIS project was presented during the kick-off meeting of the MULTIPULM project, held on 29–30 September in Athens. iPROLEPSIS partners Aristotle University of Thessaloniki (AUTH) , Faculdade de Motricidade Humana (FMH) , and Wellics participated in the meeting, which brought together researchers, clinicians, user research experts, and technology providers. Several tools developed within iPROLEPSIS – including the breathing games created by FMH and the biAURA app developed by AUTH – will be further used in MULTIPULM. These tools will be adapted to the local needs of the project’s pilot sites in Brazil, Serbia, and Türkiye, and evaluated in relevant clinical studies. This collaboration demonstrates the adaptability and broader potential of iPROLEPSIS digital tools beyond psoriatic arthritis, supporting research in other chronic conditions. SPBTU_KoM_MULTIPULM_Athens.jpg ae74e3_e25adf83abf6411cace29ed99801554f~mv2.jpg SPBTU_KoM_MULTIPULM_Athens.jpg 1/2 PREVIOUS NEXT

< BACK User Research and Co-Creation Aug 4, 2023 User Research and Co-Creation are at the core of iPROLEPSIS research process Within iPROLEPSIS , several Digital Health Tools (DHTs) will be developed with the aim to early detect the transition to PsA in PsO patients, to predict flares to allow for early intervention, and to generate personalised recommendations and personalised interventions that help manage the disease. The different DHTs to be developed are: miPROLEPSIS patient app; miPROLEPSIS healthcare practitioner dashboard; biAURA biaural sounds app; Personalised recommendation system; Personalised Gaming Suite (PGS). At iPROLEPSIS , User Research and Co-Creation form the foundation of the research process. Diverse qualitative and quantitative research methods have been employed, including interviews, observations, surveys, and usability testing, to gather data and refine our healthcare solutions. One key approach has been conducting 10 focus groups with Dutch, English, Portuguese, and Greek Psoriatic Arthritis (PsA) patients . Four prominent themes emerged from the focus group discussions: Disease Activity, Coping, Care Experience, Digital Biomarkers. To obtain more specific input from a broader population of PsA patients, a survey was created. The survey consisted of 5 sections dedicated to the following: Demographics & Technological Experience ; miPROLEPSIS Patient App - Content and Appearance; BiAURA App – Preferences; Personalised Serious Gaming Suite – Content and Appearance. Key highlights of the insights gained include: Creation of a Patient Experience Map . Psoriatic Arthritis (PsA) has a great impact on the life of those affected. Emotional wellbeing is highly related to the experienced disease activity fluctuating over time. The patient experience map relates the level of disease activity over time to the level of emotional wellbeing in a graph. The graph was created to empathise with our end users and indicate where our Digital Health Solutions might be able to help with improving their Emotional Wellbeing during various stages of disease. Development of User Personas . Engaging and relatable descriptions of user needs and desires, guiding user-centered design principles for our digital products. User Requirement Updates. Refinement of User Requirements for the Digital Health Tools based on focus group findings, ensuring that our tools meet the real needs of PsA patients. iPROLEPSIS is committed to advancing Psoriatic Arthritis (PsA) management through cutting-edge technology and empathetic design. News & Events iPROLEPSIS - news.png News & Events iPROLEPSIS - news.png 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS Plenary meeting Jun 22, 2023 iPROLEPSIS Consortium Partners Meet in Lisbon to Plan Next Steps The iPROLEPSIS consortium partners gathered in Lisbon, Portugal on June 20-21 for the 2nd Plenary meeting to review the progress and achievements of the project's work packages and plan the next steps. Over the course of two days, the consortium partners engaged in three productive workshops, each focusing on key aspects of the iPROLEPSIS project: Data Collection and Digital Biomarkers: The first workshop delved into the vital task of data collection and the development of digital biomarkers. Attendees discussed the identification of sensor and user data to be collected, including accelerometer/gyroscope data. Additionally, they explored algorithms for identifying inflammation drivers and defined user profiles to enhance personalized healthcare. System Architecture and Cloud Back-end: The second workshop centered around system architecture. The consortium partners discussed the key components of the system, including the orchestrator, and addressed critical aspects such as data management infrastructure and monitoring of app performance issues. miPROLEPSIS App and Serious Games: The third workshop involved a dynamic co-creation session, bringing together clinicians, patients, researchers, and developers. Focusing on the miPROLEPSIS app and serious games, participants explored various areas such as system architecture, key components, data management infrastructure, and app performance monitoring. The adoption of the "Crazy 8s" technique allowed for the rapid generation of a diverse range of ideas. During the third workshop patient representatives joined the session. Their valuable input and perspectives are crucial for understanding the specific needs and requirements of those who will benefit from our iPROLEPSIS project. By actively involving patient representatives, we can ensure that our solutions are truly patient-centric and tailored to their experiences and challenges. The iPROLEPSIS consortium is excited about the progress made during this meeting and is now equipped with a comprehensive plan for the next steps of the project. 3-1.jpg 3-1.jpg 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS Newsletter No. 6 Oct 9, 2024 Latest News from iPROLEPSIS Welcome to the 6th edition of the iPROLEPSIS newsletter. In this edition, we share the latest updates and progress from our project, including new developments, recent publications, and reflections on key events. iPROLEPSIS project newsletter_October 2024_ Issue No. 6 .pdf Download PDF • 4.41MB 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS at Health Data Summit 2025 Feb 12, 2025 Trustworthy AI in Digital Health iPROLEPSIS is excited to join AI-PROGNOSIS and other Horizon Europe research and innovation projects - T RUSTroke, SmartCHANGE, and STRATIFYHF - at the Health Data Summit 2025 in Brussels. Together, these projects will focus on practical approaches for building trustworthy AI-enabled digital health tools aimed at assessing disease risk and progression. During the workshop titled " Trustworthy AI in Digital Health: From Guidelines to Practice" on 19-20 March 2025, iPROLEPSIS will join experts in discussing the importance of ensuring data quality, addressing bias, and applying ethical AI principles in healthcare solutions. The workshop will cover frameworks, methods, and techniques across the AI system development lifecycle, emphasising how to build AI tools that are robust, fair, transparent, and protect privacy. Key discussion topics include: Ensuring data quality and mitigating bias in AI-driven healthcare Applying ethical AI principles throughout AI system development Balancing fairness, privacy, transparency, and robustness The session will be an opportunity for iPROLEPSIS and its partners to contribute to advancing the responsible use of AI in healthcare and discuss solutions for improving digital health tools. Event details: Health Data Summit 2025 Programme details: Summit Programme 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS Newsletter No. 7 Jan 28, 2025 Latest News from iPROLEPSIS Welcome to the 7th edition of the iPROLEPSIS newsletter. In this edition, we share the latest updates and progress from our project, including new developments, recent publications, and reflections on key events. iPROLEPSIS project newsletter_Jan 2025_Issue No. 7 .pdf Download PDF • 5.60MB 1/1 PREVIOUS NEXT

Download needed deliverables for iProlepsis project for psoriatic arthritis. Project deliverables D1.2 Data managmeent plan (initial version) WP1 - Management and coordination Read More D2.3 The iPROLEPSIS trustworthy AI framework WP2 - Knowledge mining, foundation and participatory design Read More D6.1 Project branding and communication channels WP6 - Dissemination, communication and exploitation Read More D2.1 Initial report on user research and co-creation process WP2 - Knowledge mining, foundation and participatory design Read More D4.2 The iPROLEPSIS patient and HCP apps (study version) WP4 - Development of the iPROLEPSIS digital health ecosystem for personalised preventive care Read More D6.2 Dissemination, exploitation and communication plan WP6 - Dissemination, communication and exploitation Read More D2.2 Initial report on the state-of-the-art and datasets WP2 - Knowledge mining, foundation and participatory design Read More D5.1 Study initiation package (iPROLEPSIS-PDPID study) WP5 - Clinical studies Read More D6.3 First report on project visibility and educational material WP6 - Dissemination, communication and exploitation Read More

< BACK Ongoing preparation for the iPROLEPSIS-PDPID study Mar 4, 2024 iPROLEPSIS-PDPID Study: Advancing Psoriatic Arthritis through Innovative Digital Biomarkers Patients with Psoriatic arthritis (PsA) experience difficulties in dealing with unpredictable disease activity, which can affect their quality of life. Developing a digital biomarker using a smartphone and smartwatch would allow for unobtrusive monitoring of the disease activity in these patients. Besides, understanding what factors trigger flare would allow for better disease control. The iPROLEPSIS-PDPID study is a multicentre observational cohort study that aims to develop an unobtrusive and affordable digital biomarker capable of detecting changes in disease activity, including flare, and to identify triggers of flare in patients with PsA. The study will be conducted in four countries: the Netherlands, the UK, Portugal and Greece. Ethical approval for initiating the iPROLEPSIS-PDPID study in the Netherlands and the UK has been granted. The OpenClinica platform will be used in the collection and storage of data for the iPROLEPSIS-PDPID study. Future steps include obtaining ethical approvals for Portugal and Greece as well as local approvals from centres participating in each country, and inclusion of patients from each participating country. The miPROLEPSIS phone app , currently under development, will be used in this study. The app will be installed on the patient smartphone and utilised as a data collector, which will be then used for algorithms development and training. The app will measure physical activity, the length of sleep, self-registered flare, and register daily pain, fatigue, sleep and morning stiffness. The Garmin smartwatch Vivoactive 5 device will be used to collect data on physical activity, heart rate, heart rate variability and sleep quality. The collected data from Garmin will be downloaded from the miPROLEPSIS app by Wellics software (developer in the project), which allows extracting, visualising and exporting collected both company-processed data, as well as raw data. 10.png 13.png 14.png 10.png 1/5 PREVIOUS NEXT

Learning Hub Explore resources to help you understand and manage psoriatic arthritis. Learning hub Key Facts Handbook News Feed Quizzes Search What is psoriatic arthritis? See related Handbook section PREVIOUS NEXT